Boryung Management

Management Kriterienprüfungen 0/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Jay Kim

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	no data
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	keine Daten

Jüngste Management Updates

Recent updates

Is Boryung Pharmaceutical Co., Ltd.'s (KRX:003850) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Feb 09

Do Institutions Own Boryung Pharmaceutical Co., Ltd. (KRX:003850) Shares?

Jan 25

Should You Use Boryung Pharmaceutical's (KRX:003850) Statutory Earnings To Analyse It?

Jan 10

If You Had Bought Boryung Pharmaceutical (KRX:003850) Shares Three Years Ago You'd Have Earned 122% Returns

Dec 23

Is Boryung Pharmaceutical (KRX:003850) A Risky Investment?

Dec 08

Would Boryung Pharmaceutical Co., Ltd. (KRX:003850) Be Valuable To Income Investors?

Nov 23

Geschäftsführer

Jay Kim

no data

Amtszeit

Mr. Jay Kim serves as Chief Executive Officer of Boryung Corporation.

Boryung Management

Management Kriterienprüfungen 0/4

Wichtige Informationen

Jüngste Management Updates

Boryung Corporation, Annual General Meeting, Mar 26, 2024

Less than half of directors are independent

Less than half of directors are independent

Boryung Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2021

Recent updates

Why We're Not Concerned About Boryung Corporation's (KRX:003850) Share Price

Full year 2023 earnings: EPS misses analyst expectations

Boryung Corporation, Annual General Meeting, Mar 26, 2024

Upcoming dividend of ₩100.00 per share at 0.9% yield

Boryung Corporation(KOSE:A003850) dropped from KOSPI 200 Index

Investor sentiment improves as stock rises 17%

New major risk - Revenue and earnings growth

Boryung Corporation Partners with Axiom Space and Aurelia Institute to Launch the "2023 Humans in Space" Program

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Upcoming dividend of ₩100.00 per share

Less than half of directors are independent

Price target decreased to ₩15,500

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Upcoming dividend of ₩75.77 per share

Price target increased to ₩17,500

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS ₩400 (vs ₩180 in 1Q 2020)

Investor sentiment deteriorated over the past week

A Look At The Fair Value Of Boryung Pharmaceutical Co., Ltd. (KRX:003850)

Full year 2020 earnings released: EPS ₩554 (vs ₩698 in FY 2019)

Boryung Pharmaceutical (KRX:003850) Has A Pretty Healthy Balance Sheet

Here's How We Evaluate Boryung Pharmaceutical Co., Ltd.'s (KRX:003850) Dividend

Boryung Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2021

Is Boryung Pharmaceutical Co., Ltd.'s (KRX:003850) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Do Institutions Own Boryung Pharmaceutical Co., Ltd. (KRX:003850) Shares?

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Should You Use Boryung Pharmaceutical's (KRX:003850) Statutory Earnings To Analyse It?

New 90-day high: ₩20,500

If You Had Bought Boryung Pharmaceutical (KRX:003850) Shares Three Years Ago You'd Have Earned 122% Returns

Is Boryung Pharmaceutical (KRX:003850) A Risky Investment?

Market pulls back on stock over the past week

Price target raised to ₩21,000

New 90-day high: ₩20,700

Market bids up stock over the past week

Would Boryung Pharmaceutical Co., Ltd. (KRX:003850) Be Valuable To Income Investors?

Third quarter 2020 earnings released: EPS ₩168

New 90-day low: ₩14,750

New 90-day low: ₩15,250

Price target raised to ₩21,000

First half earnings released

New 90-day high - ₩17,550

Geschäftsführer

Amtszeit